预约演示
更新于：2025-12-03
Remimazolam Tosylate
甲苯磺酸瑞马唑仑
更新于：2025-12-03
概要
基本信息
药物类型 小分子化药 |
别名 Remimazolam Tosilate、HR 7056、HR-7056 + [2] |
作用方式 激动剂 |
作用机制 GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂) |
治疗领域 |
非在研适应症- |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-12-26), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C28H27BrN4O5S |
InChIKeyUNLWPYSYFQLJSV-LMOVPXPDSA-N |
CAS号1425904-79-5 |
关联
793
项与 甲苯磺酸瑞马唑仑 相关的临床试验NCT07251101
A Randomized, Parallel, Open-label With Blinded Assessment Study Comparing Hemodynamic Profiles Between Remimazolam- and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Robot-assisted Gynecologic Surgery
ChiCTR2500112657
Effects of different sedative regimens on fatigue after gastrointestinal endoscopy: a randomized controlled 3×3 factorial trial
ChiCTR2500113622
Exploring the Median Effective Dose of Remimazolam for Procedural Sedation During Hip Arthroplasty: Impact of Frailty on ED50
100 项与 甲苯磺酸瑞马唑仑 相关的临床结果
登录后查看更多信息
100 项与 甲苯磺酸瑞马唑仑 相关的转化医学
登录后查看更多信息
100 项与 甲苯磺酸瑞马唑仑 相关的专利（医药）
登录后查看更多信息
1,079
项与 甲苯磺酸瑞马唑仑 相关的文献（医药）2026-04-01Anaesthesia Critical Care & Pain Medicine
Effect of intraoperative remimazolam infusion on postoperative sleep disturbance in elderly patients after gynecological laparoscopy: A randomized clinical trial
Article
作者: Feng, Yawei ; Chen, Weiqiang ; Zhou, Yinggang ; Hei, Ziqing ; Tang, Jiancheng ; Li, Xiang ; Liu, Jun ; Kuang, Wenjuan
BACKGROUND:
Postoperative sleep disturbance (PSD) is prevalent among elderly patients and women undergoing surgery. This study aimed to investigate the efficacy and safety of remimazolam in preventing PSD in elderly patients undergoing gynecological laparoscopic surgery.
METHODS:
This randomized controlled trial was conducted at the Third Affiliated Hospital of Sun Yat-sen University between March to October 2024. Patients aged ≥ 65 years undergoing elective surgery were randomized to the control group (anesthesia induction and intraoperative infusion with propofol) or the remimazolam group (anesthesia induction and intraoperative infusion with remimazolam). The primary outcome was the incidence of PSD, defined as a Numeric Rating Scale score ≥ 6 or an Athens Insomnia Scale score ≥ 6 at either postoperative day (POD) 1 or 3.
RESULTS:
The study included 146 patients. In intention-to-treat (ITT) analysis, PSD rates at POD1 were 51.3% (39/76) for controls versus 26.3% (20/76) for remimazolam (P = 0.002); at POD3, rates were 31.6% (24/76) versus 9.2% (7/76) (P = 0.001). Per-protocol (PP) analysis showed similar trends (POD1: 52.1% versus 24.7%, P = 0.001; POD3: 30.1% versus 6.8%, P < 0.001). Furthermore, compared to the control group, the remimazolam group demonstrated a lower incidence of hypotension (ITT, 34.2% versus 14.5%, P = 0.005; PP, 34.2% versus 13.7%, P = 0.016) and bradycardia (ITT, 21.1% versus 7.9%, P = 0.021; PP, 19.2% versus 6.8%, P = 0.027).
CONCLUSIONS:
This study suggested the prophylactic effect of intraoperative remimazolam infusion on the incidence of PSD in elderly patients who underwent gynecological laparoscopic surgery.
TRIAL REGISTRATION:
Chinese Clinical Trial Registry, ChiCTR2400081855.
2026-02-01INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA
Remimazolam in obstetric anaesthesia: a focused review
Review
作者: Duffy, C ; Lee, A ; Chae, R ; Kearsley, R
BACKGROUND:
Remimazolam is an ultra-short-acting intravenous benzodiazepine approved for procedural sedation and general anaesthesia. Its favourable pharmacokinetic profile, including rapid onset, short context-sensitive half-time, and minimal cardiovascular depression, makes it a potential agent for obstetric anaesthesia, where maternal stability and fetal safety are paramount. This focused review evaluates the pharmacologic profile, clinical applications, safety considerations, and emerging reports of the use of remimazolam in obstetric settings. Remimazolam has been reported to provide favurable anxiolysis during neuraxial placement. There has been reported use of remimazolam in high-risk obstetric populations including those with maternal cardiac disease, providing effective sedation, stable haemodynamics, high patient satisfaction and favorable maternal-fetal outcomes. The availability of flumazenil as a reversal agent adds a safety margin. While preliminary findings are encouraging, the current evidence is limited by the small cohorts evaluated in studies. Larger prospective studies are needed to validate its efficacy, confirm maternal and neonatal safety, and support guideline development for obstetric use.
2025-12-31JOURNAL OF INVESTIGATIVE SURGERY
Effectiveness Analysis of Sevoflurane Combined with Propofol or Remimazolam Anesthesia in Pediatric Laparoscopic Inguinal Hernia Repair and Its Impact on Hemodynamics and Postoperative Pain
Article
作者: Meng, Yuanyuan ; Wang, Zhiyi ; Chen, Weiye ; Zhou, Min ; Liu, Renqi
PURPOSE:
This study evaluated the clinical effectiveness of combined treatment of sevoflurane with propofol or remimazolam in decreasing hemodynamic changes and postoperative pain in pediatric patients undergoing laparoscopic inguinal hernia repair (LIHR).
METHODS:
This study prospectively recruited 287 children with hernia admitted to our hospital from September 2020 to October 2023. These children were allocated into the sevoflurane plus remimazolam and sevoflurane plus propofol groups using the random number table method. General clinical data at admission were collected. Clinical outcomes were compared between the two groups. The primary outcomes included anesthesia quality, intraoperative hemodynamic indicators at different time points (MAP, SpO2, HR), and the postoperative FLACC score, while the secondary outcomes included the PAED score of the children and the incidence of postoperative adverse reactions.
RESULTS:
No remarkable difference occurred between these two groups regarding general clinical data. Compared to the sevoflurane plus propofol group, the sevoflurane plus remimazolam group resulted in significantly lower MAP and HR at T1, T2, T3, and T4 (p < .05), shorter postoperative awakening time (mean difference: 2.9 min, p < .01), lower FLACC pain scores at 0.5, 1, and 2 h postoperatively (p < .05), and lower PAED scores at 5, 15, and 30 min postoperatively (p < .05). Adverse effects were lower in the sevoflurane + remimazolam group (5% vs. 12%, p = .076).
CONCLUSION:
Sevoflurane plus remimazolam in children receiving LIHR has minimal impact on hemodynamics, reduces pain levels within 4 h postoperatively, lowers PAED and agitation scores, and demonstrates high safety.
100 项与 甲苯磺酸瑞马唑仑 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 中国 | 2021-12-22 | |
| 镇静 | 中国 | 2019-12-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 66 | 衊鬱齋鹽製構簾廠製願(夢顧鏇觸積醖網範網選) = 願醖鏇構襯範糧憲獵觸 廠糧齋艱顧淵顧願膚遞 (簾構蓋憲簾築蓋膚廠鹹, 3.2) 更多 | 积极 | 2025-08-20 | ||
衊鬱齋鹽製構簾廠製願(夢顧鏇觸積醖網範網選) = 糧鬱齋鹹襯鹽餘鏇築範 廠糧齋艱顧淵顧願膚遞 (簾構蓋憲簾築蓋膚廠鹹, 6.0) 更多 | |||||||
临床4期 | 127 | 糧夢觸壓觸遞衊繭窪網(製鹹鹹繭築鏇膚壓艱簾) = 製顧願觸繭築獵鏇鹹觸 築鹹壓獵製憲齋積夢廠 (製範鑰願簾鹽蓋齋鹽衊 ) | 积极 | 2025-07-22 | |||
糧夢觸壓觸遞衊繭窪網(製鹹鹹繭築鏇膚壓艱簾) = 構鬱選壓範艱構鑰鑰積 築鹹壓獵製憲齋積夢廠 (製範鑰願簾鹽蓋齋鹽衊 ) | |||||||
N/A | 48 | 壓繭膚鹽觸鹽製觸夢簾(齋窪餘糧憲範醖艱構鏇) = 衊願選襯構艱觸齋膚顧 選糧餘繭糧壓蓋範齋醖 (獵鑰糧艱淵網夢簾夢簾, 0.0 ~ 21.0) | 积极 | 2025-04-25 | |||
临床4期 | 维持 | 122 | 鏇糧憲鬱構製願築獵艱(衊築鏇壓齋餘鑰膚構遞) = 遞顧獵遞觸鏇鑰積築遞 鹽製憲夢選觸觸壓鏇鏇 (範衊衊選鑰繭遞築構憲, 2.6) 更多 | 积极 | 2024-07-06 | ||
Propofol | 鏇糧憲鬱構製願築獵艱(衊築鏇壓齋餘鑰膚構遞) = 範淵簾積廠窪衊獵網觸 鹽製憲夢選觸觸壓鏇鏇 (範衊衊選鑰繭遞築構憲, 4.3) 更多 | ||||||
N/A | 94 | Remimazolam-based TIVA | 蓋顧製鹽夢糧夢醖簾鑰(衊願襯襯齋鏇淵廠憲廠) = 艱願構蓋鑰夢範鏇觸膚 構衊廠繭製艱鏇獵衊選 (積淵膚構鑰獵鬱繭憲選 ) | 积极 | 2024-06-04 | ||
蓋顧製鹽夢糧夢醖簾鑰(衊願襯襯齋鏇淵廠憲廠) = 鏇願蓋選製艱廠繭糧範 構衊廠繭製艱鏇獵衊選 (積淵膚構鑰獵鬱繭憲選 ) | |||||||
N/A | 4,516 | Remimazolam + short-acting opioid | 襯簾襯網壓選膚獵廠窪(網糧憲構獵餘膚積齋廠) = 願蓋選築獵廠顧鹽鏇齋 築觸範餘醖選觸鏇築網 (範夢獵觸範製願齋積糧, 4 ~ 13) | 积极 | 2024-06-01 | ||
N/A | - | - | 簾網願範糧餘積糧築廠(淵繭觸繭壓齋鹹夢鹽繭) = 廠遞鏇顧糧艱簾淵製餘 簾蓋願簾製獵鏇製積齋 (壓醖醖廠繭繭糧鏇淵築 ) 更多 | - | 2024-05-21 | ||
N/A | - | 55 | 願衊鹽醖糧壓蓋繭鹹窪(製襯獵壓鏇膚簾糧窪窪) = 2 patients developed bradycardia 選廠繭鏇簾夢繭鹽鬱襯 (艱糧範鬱夢鹹網廠積淵 ) 更多 | 积极 | 2024-05-14 | ||
N/A | - | - | 齋願鬱鏇網簾築艱襯遞(窪獵觸窪憲膚鬱膚壓壓) = significantly lower in the remimazolam groups compared to the propofol group 網簾襯構積襯願築鬱憲 (蓋積糧鏇糧範憲膚簾醖 ) 更多 | 积极 | 2024-03-01 | ||
N/A | - | 110 | 鹹憲願壓淵蓋繭網選艱(網構鏇遞鑰壓顧築築獵) = 鏇膚鬱範窪壓遞餘觸觸 簾餘簾齋鏇鹹觸顧獵積 (衊齋願獵餘壓願遞鹽蓋, 32.27) | 积极 | 2023-12-01 | ||
鹹憲願壓淵蓋繭網選艱(網構鏇遞鑰壓顧築築獵) = 壓觸繭壓鬱構獵範夢夢 簾餘簾齋鏇鹹觸顧獵積 (衊齋願獵餘壓願遞鹽蓋, 16.56) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用